PanelCAT: an Open-Source Comparative Analysis Tool for

2 Next-Generation Sequencing Panel Target Regions

- 3 André Oszwald¹, Lucia Zisser², Eva Compérat¹, Leonhard Müllauer¹
- ⁴ ¹ Department of Pathology, Medical University of Vienna, Währinger Gürtel 18-20, 1090 Vienna,
- 5 Austria
- 6 ²Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear
- 7 Medicine., Medical University of Vienna, Währinger Gürtel 18-20, 1090 Vienna, Austria

8 Abstract

- 9 Multi-gene next-generation sequencing (NGS) panels have become a routine diagnostic method in
- 10 the contemporary practice of personalised medicine. To avoid inadequate test choice or
- 11 interpretation, a detailed understanding of the precise panel target regions is required. However, the
- 12 necessary bioinformatic expertise is not always available, and publicly accessible and easily
- 13 interpretable analyses of target regions are scarce. To address this critical knowledge gap, we present
- 14 the Panel Comparative Analysis Tool (PanelCAT) an open-source application to analyze, visualize and
- 15 compare NGS panel DNA target regions. PanelCat uses RefSeq, ClinVar and COSMIC cancer mutation
- 16 census databases to quantify the exon and mutation coverage of target regions and provides
- 17 interactive graphical representations and search functions to inspect the results. We demonstrate
- 18 the utility of PanelCAT by analyzing two large NGS panels (Illumina TSO500 and Qiagen pan-cancer
- 19 panel) to validate the advertized target genes, quantify targeted exons and mutations, and identify
- 20 differences between panels. PanelCat will enable institutions and researchers to catalogue and
- 21 visualize NGS panel target regions independent of the manufacturer, promote transparency of panel
- 22 limitations, and share this information with employees and requisitioners.

23 Introduction

| 24 | Precision oncology routinely involves next-generation sequencing (NGS) of tumor DNA to identify |
|----|---|
| 25 | therapeutically actionable targets or diagnostically relevant mutations that critically direct patient |
| 26 | management ¹ . Most multi-gene sequencing panels do not cover entire genes, but only variable |
| 27 | portions of genes that are considered most relevant, i.e., predominantly protein-coding sequences |
| 28 | and tumor mutational hotspots. For this reason, both the choice of an adequate test and its |
| 29 | interpretation, especially regarding the certainty of negative findings, crucially depend on detailed |
| 30 | knowledge of the portions of genes and genetic alterations that may be assessed by a panel. |
| 31 | Target regions of commercial NGS panels are typically specified in a panel-specific BED file by a list of |
| 32 | chromosome numbers, start and stop coordinates ² . Although this information is an essential part of |
| 33 | the test documentation, it is not useful to understand panel target regions in detail without further |
| 34 | analysis for several reasons: it does not inform on the non-targeted portions of genes without |
| 35 | comparison to a reference genome; the provided information on target genes, transcripts and exons |
| 36 | is not updated alongside the transcript databases (e.g., $RefSeq^3$); the target regions must be |
| 37 | systematically compared to mutation/variant databases in order to determine pathogenic mutations |
| 38 | that can be detected; lastly, genomic positions with known high rates of erroneous variant calls are |
| 39 | often masked during secondary analysis, but these positions are defined in separate files. |
| 40 | Consequently, the lack of detailed publicly available data on precise panel targets, and the barriers to |
| 41 | generate it due to the required bioinformatic expertise, portend the risk of inadequate test choice |
| 42 | and test misinterpretation. To reduce this risk, we developed the "Panel Comparative Analysis Tool" |
| 43 | (PanelCAT), an application that allows to analyze, visualize and compare DNA target regions of NGS |
| 44 | panels within a user-friendly interface, and provides a platform to clearly communicate this |
| 45 | information to others. We demonstrate the use of this tool by analyzing two large multi-gene NGS |
| 46 | panels, the Illumina TrueSight Oncology 500 (TSO) and Qiagen Pan-Cancer (QPC) Panel, in order to |

- 47 provide a more detailed documentation of their targeted genes, exons, known pathogenic mutations,
- 48 and differences between the panels, than has been available to date.

49 Materials and Methods

50 PanelCat code

- 51 PanelCat code was created, and all analyses were performed, in R⁴ v4.3.0 within RStudio v2023.03.0.
- 52 Analysis of genomic ranges (target regions and variant coordinates) were performed using the
- 53 GenomicFeatures⁵ package. Graphs were drawn using ggplot2⁶ and plotly⁷ packages. A browser-
- 54 based implementation of the script was created using ShinyR⁸. PanelCat is provided under the open-
- 55 source license AGPLv3 and the source code, and R session information is available at
- 56 <u>https://github.com/aoszwald/panelcat</u>. The basic procedure of the panel analysis is outlined below.

57 PanelCat accepts target region files as input (containing columns for chromosome, start, and end

58 position of target regions), and optionally the mask region file (also containing chromosome, start

59 and end coordinates). The application first determines the intersection between the panel target

60 regions and RefSeq³ exon coordinates in order to systematically identify target genes, and

61 subsequently all exon ranges of target genes. The exon ranges of each targeted gene are then

62 intersected with the panel target regions to quantify the targeted portion of protein coding bases per

63 gene. Targeted mutations are then identified by intersection of the panel target regions with the

64 coordinates of mutations in the ClinVar⁹ and COSMIC¹⁰ databases. Optionally, the mask file is

incorporated in the analysis to identify and determine the portion of masked bases and mutations.

66 The summarized output data are combined into lists of items and saved as R data objects. Panels that

67 were previously analyzed and saved in this form are pre-loaded the next time the application is

68 started. The panel output files can also be used for analysis outside of PanelCat; within R, the panel

- 69 data and listed sub-items can be accessed via the "\$" operator. In the course of this study, individual
- 70 data were accessed in this way and further processed in R independently of the PanelCat functions

- 71 to answer specific questions, including the cumulative percentage of non-targeted mutations, and
- 72 discrepancies between the advertized gene list and the confirmed gene list.

73 Data sources

- 74 BED files indicating target regions of NGS panels and corresponding mask files, including Illumina
- 75 TSO500 and Qiagen Pan-Cancer Panels, were obtained from the customer support of the
- 76 manufacturers, or obtained in the course of using a product. The TSO500 mask file was provided by
- 77 Illumina. These files are not provided as part of PanelCat.
- 78 The following databases are not provided as part of the software download, and need to be either
- 79 downloaded manually (COSMIC) or automatically by PanelCat (ClinVar and ClinVar assembly report,
- 80 RefSeq):
- 81 ClinVar data (last accessed 25.05.2023) was obtained from
- 82 <u>https://ftp.ncbi.nlm.nih.gov/pub/clinvar/vcf_GRCh37/weekly/clinvar.vcf.gz</u>. The COSMIC cancer
- 83 mutation census data (v98, last accessed 23.05.2023) was obtained from
- 84 https://cancer.sanger.ac.uk/cosmic/download. RefSeq data (last accessed 25.05.2023) was obtained
- 85 from
- 86 https://ftp.ncbi.nlm.nih.gov/refseq/H_sapiens/annotation/GRCh37_latest/refseq_identifiers/GRCh3
- 87 7_latest_genomic.gff.gz, and the GrCh37. The NCBI assembly report was obtained (last accessed
- 88 25.05.2023) from
- 89 https://ftp.ncbi.nlm.nih.gov/genomes/refseq/vertebrate_mammalian/Homo_sapiens/annotation_rel
- 90 eases/105.20220307/GCF_000001405.25_GRCh37.p13/GCF_000001405.25_GRCh37.p13_assembly_
- 91 report.txt.
- 92 Results
- 93 General function of PanelCat
- 94 PanelCat (https://github.com/aoszwald/panelcat and https://aoszwald.shinyapps.io/panelcat/)
- 95 provides functions to automatically distill descriptive information from panel target region files and

| 96 | public databases, and to display this data to facilitate evaluation and comparison of panels. To |
|-----|---|
| 97 | analyze a panel, PanelCat is provided with the target region file (typically with a .bed file suffix, but |
| 98 | others may be acceptable), and optionally a mask file (indicating regions where variant calls are |
| 99 | unreliable and will be filtered out). The application then determines the overlap between target |
| 100 | regions and protein-coding bases per gene in RefSeq 3 , known pathogenic and likely pathogenic |
| 101 | mutations in ClinVar ⁹ and tier 1-3 oncogenic mutations in COSMIC ¹⁰ cancer mutation census (CMC) |
| 102 | databases. The output data is saved in a compact form that can be used in PanelCat or explored |
| 103 | independently in R Statistics ⁴ . |
| 104 | The application provides several visualization options to analyze and compare panels, briefly outlined |
| 105 | here. The first ention is a sector plot, where users can contract target enverage metrics of DefCon |
| 105 | nere. The first option is a scatter plot, where users can contrast target coverage metrics of kerseq, |
| 106 | ClinVar and COSMIC databases from all analyzed panels. This function can be used to compare |
| 107 | between panels, e.g., to determine differences in target gene coverage (Fig. 1A), or within panels, |
| 108 | e.g., to evaluate the relationship between coverage of protein-coding bases and pathogenic |
| 109 | mutations. The second option is a horizontal column plot showing per-gene coverage, and the |
| 110 | masked portion, of protein-coding bases, ClinVar variants and COSMIC mutations, whereby users can |
| 111 | select multiple panels for comparison (Fig. 1B). The third visualization is a column plot optimized to |
| 112 | search for and display one or multiple specific genes of interest across several (or all) analyzed |
| 113 | panels, with indication of a panel that targets all searched genes (Fig. 1C). The fourth visualization is |
| 114 | a column plot of the estimated frequency of COSMIC CMC mutations that are not targeted by the |
| 115 | panels, both in target genes only and in all genes, with and without considering variant masking (Fig. |
| 116 | 1D). Lastly, PanelCat provides a graph to compare base coverage of individual exons per transcript |
| 117 | between two panels in paired violin plots (Fig. 1E). |
| 118 | Besides graphs, PanelCat provides table views to compare raw numerical data, or investigate the |
| 119 | coverage of specific exons and mutations. In the first option, users can inspect the PanelCat output |
| | |

120 data (representing the raw data from which the graphs are generated), whereby multiple panels and

metrics can be simultaneously displayed and searched for specific genes. The second option displays
the coverage of each exon of every transcript of all target genes of a panel (Fig. 1F). Similarly, the
third and fourth options provide for each panel a complete list of targeted ClinVar variants and
COSMIC mutations, including the ability to display masked variants. The exon, ClinVar and COSMIC
tables can be searched/filtered for each column independently, e.g., for specific genes, transcripts,
exons, coding or amino acid changes, or genome coordinates.
When run locally, PanelCat automatically obtains the current ClinVar (released weekly) and RefSeq

databases upon first use. These, along with all previously processed panels, can be updated in a

single step; previous versions of databases and panel analyses are stored for later reference and

130 documentation. The COSMIC CMC database (updated every several months) requires manual

131 download and replacement of the local file.

132 In summary, PanelCat offers multiple useful and intuitive functions to substantially improve the

133 transparency and accessibility of NGS panel target region documentation. The newly developed tool

134 was next used to analyze two very large panels currently used in both clinical and research settings;

the Illumina TrueSight Oncology 500 (TSO) and the Qiagen Pan-Cancer (QPC) panel. Although the

136 target regions can be requested as part of the panel documentation, the explicit coverage of genes

137 and mutations are not provided. However, informed clinical use requires detailed information, so we

used PanelCat to characterize their target regions in detail and explore their subtle differences.

139 Mutation coverage in Qiagen PanCancer panel is similar or greater than TSO500,

140 despite lower exon coverage

141 In their respective product documentation, the TSO and QPC panels advertise the same 523 gene

142 targets for analysis of small variants (e.g, SNV, insertions and deletions). We first compared the

advertized genes to the target genes identified using PanelCat. The QPC target regions overlapped

144 with exons of 603 genes, including all advertized genes. By contrast, the TSO target regions

overlapped with exons of 625 genes, but these included only 521 of the 523 advertised targets. The

146 two remaining target genes (HLA-B and HLA-C) do not overlap with the TSO target regions;

| 147 | accordingly, we did not find any variant calls in HLA-B or HLA-C in a representative set of 400 samples |
|-----|---|
| 148 | analyzed with the TSO panel (including unfiltered variant call files in 10 samples). Alterations in HLA-I |
| 149 | genes have been postulated to promote tumor evasion of immune surveillance, e.g., by restricting |
| 150 | neoantigen presentation ^{11,12} , although no guidelines recommendations to test HLA genes exist |
| 151 | momentarily. |

152 We next identified the targeted exon-coding bases of each gene. We first searched for genes with the

153 greatest coverage and found that in the TSO, 20 genes had exon coverage > 95% (including NAB2,

154 TERC, CD74, TFE3, KIF5B, EML4, EWSR1, FLI1, ETV1, ETV5, PAX3, all over 99%), whereas in the QPC, it

155 was only six (TERC, ZRSR2, ATR, POLD1, KMT2B, RECQL4). We found a strong direct correlation

between the base coverage of TSO and QPC panels (Pearson's r = 0.81, p < 2e-16), and no significant

difference in mean exon base coverage per gene (TSO 50.3% vs. QPC 48.4%, p = 0.23) (Fig 2A). We

identified target genes where relative coverage was considerably greater in the TSO than in the QPC,

including NTRK2, ETV1, AKT3, ERG, and PAX7, but only few genes with greater coverage in the QPC

160 panel, notably PMS2, TERT, HLA-B and HLA-C (Fig. 2B). Importantly, four targeted genes (HLA-A,

161 KMT2B, KMT2C, KMT2D) showed total masking of all target regions in the TSO panel (but not in the

162 QPC, which does not use a mask file). Accordingly, we did not find any variants calls in these genes in

a representative set of 400 samples analyzed with the TSO panel.

164 ClinVar lists approximately 50,000 known variants labelled "pathogenic" or "likely pathogenic" in the

advertized TSO and QPC target genes. While the TSO targeted 92.5% of these variants (94.8%

166 without variant masking), the QPC targeted 97.4%, despite lower exon coverage. Consequently,

167 targeting of all pathogenic variants was achieved for 182 genes in the TSO panel (200 without

168 masking), and 223 genes in the QPC panel. In the TSO panel, no pathogenic variants were targeted in

169 8 genes (of which 6 were due to variant masking), whereas in the QPC it was only three. In both

panels, the majority (QPC: 51%, TSO: 64%) of non-targeted variants occurred in two similar sets of

171 only 10 genes, in both cases including NF1 and the DNA repair genes MLH1, MSH2, BRCA1, BRCA2 172 and ATM (Supplemental Table 1). Most differences between panels were attributable to either 173 greater coverage in the QPC (PMS2, TERT) or extensive masking in the TSO (KMT2B, KMT2C, KMT2D) 174 (Fig 2C, 2D). 175 The COSMIC cancer mutation census database (CMC, v98) lists ~43.000 unique mutations occurring 176 in genes targeted by the TSO and QPC panels, of which the majority (93.4%, or 99.5% without variant 177 masking) are targeted by the TSO, and all by the QPC (100%) (Fig. 2E, 2F). Due to masking, no 178 mutations are targeted by the TSO500 in HLA-A, KMT2C and KMT2D. Independent of masking, the 179 QPC panel more extensively targeted mutations in NF1, TERT and PMS2 than the TSO. We estimated 180 the frequency of samples to harbor non-targeted mutations by calculating the positive sample 181 proportion of unique mutations in the CMC dataset, and cumulating the frequency all non-targeted 182 mutations. The rate of non-covered CMC tier 1-3 mutations in targeted genes per sample was lower 183 in the QPC (0.005) than in the TSO (0.14, 0.02 without masking), suggesting that one in eight (TSO, or

one in 50 without masking) or one in 200 (QPC) samples would harbor oncogenic mutations that

185 cannot be detected with the panels, in one of the panel target genes.

186 Discussion

187 Detailed knowledge of the target regions of NGS panels is important for the correct choice and

interpretation of molecular tests, but is not typically well illustrated by the test manufacturer, and

usually requires bioinformatic analysis to acquire. In this study, we present PanelCat, a novel open-

source tool that can be used by laboratories or NGS panel distributors to analyze NGS target regions

and share this information to enable more informed decisions. A limitation of PanelCat is that it does

192 not assess fusion or copy number events detected by panels, but respective features may be

implemented in future.

PanelCat enables rapid assessment and rich visualisation of the designed target regions of NGS
panels without bioinformatic expertise. As an example, we expanded in detail on the existing and

| 196 | incomplete documentation of two large NGS tests (Illumina TSO500 and Qiagen Pan-Cancer). |
|-----|---|
| 197 | PanelCat quantified precise exon coverage and identified of genes with poor coverage, extensive |
| 198 | variant masking, differences between panels, and even discrepancies to the advertised gene list. |
| 199 | Thus, we found that unlike the QPC, the TSO500 does not target HLA-B and HLA-C; that KMT2B, |
| 200 | KMT2C and KMT2D are extensively masked in the TSO500 and will not yield variant calls after |
| 201 | filtering, and that PMS2 and TERT are substantially better covered in the QPC panel independent of |
| 202 | variant masking. In addition, we used PanelCat to describe the different coverage of individual exons |
| 203 | of PMS2 in the panels. |
| | |

PanelCat is different from the Panel Informativity Optimizer (PIO) method, previously demonstrated

204

to assist in optimizing NGS panel design¹³. Because PanelCat does not generate new target regions, it 205 206 only indirectly assists in panel design by highlighting deficits in exon or mutation coverage in 207 particular genes of interest. Compared to PIO, PanelCat provides superior functions to analyze and 208 compare existing (or proposed) panels. Crucially, PIO cannot process complex target regions or 209 conventional BED-format files, only lists of complete genes or exons. Most panels target incomplete 210 genes or exons, and would thus be inaccurately represented using PIO. Consequently, the limited 211 panel benchmarking functions of PIO cannot inform on precise exons coverage, whereas PanelCat 212 provides detailed information on the level of genes, exons and individual mutations. In contrast to 213 PIO, which provides a linear data pipeline from input to output, PanelCat is a platform to collect 214 panel analyses and visualize them for frequent inspection in a routine clinical setting. In summary, 215 PanelCat provides opportunities that have not yet been demonstrated with previous methods, albeit 216 with features designed more for panel end-users than panel developers. 217 In contrast to PIO, PanelCat does not use a variety of mutation databases to account for the 218 heterogeneity of mutation frequencies across different disease entities. Although panels are often 219 designed for specific disease entities or groups thereof, many widely used panels (e.g., Thermo 220 Fisher Oncomine Focus, or Illumina TSO500) were designed to cover a wide range of disease entities,

and we therefore also chose a disease-agnostic approach for PanelCat. However, the variant

- databases used by PanelCat can be pre-processed by users to focus the analysis entirely on
- 223 mutations that are relevant in a specific disease context.
- 224 PanelCat was designed for users with limited or no IT support. For this reason, the software is
- designed to function on a local device (without installation of software besides R statistics); however,
- a slightly modified script can be hosted using ShinyServer to provide a network service. PanelCat
- 227 reference databases can be easily updated, and stored panel analyses can be managed within the
- 228 operating system's file system.
- 229 Although multi-gene NGS panels are currently the standard procedure in many institutions, routine
- 230 whole exome sequencing of tumor specimens is being increasingly performed. Due to the high
- 231 performance of the underlying packages⁵, PanelCat could be used to analyze target regions of whole
- exome panels. However, the increased rendering time of some of the implemented visualization
- 233 methods could be impractical. Nevertheless, the PanelCat output data, saved as R objects, could be
- used outside of PanelCat to plot custom graphs demanding less computation.
- 235 In conclusion, we present PanelCat as a powerful solution to current shortcomings in the
- presentation, analysis and awareness of NGS panel target regions. We believe this software will
- 237 improve the transparency of NGS panels and facilitate more informed decisions in test choice and
- interpretation, thus constituting a valuable addition to the expanding repertoire of available tools.
- 239 References
- Mosele, F. *et al.* Recommendations for the use of next-generation sequencing (NGS) for patients
 with metastatic cancers: a report from the ESMO Precision Medicine Working Group. *Ann. Oncol.*
- **31**, 1491–1505 (2020).
- 243 2. Niu, J., Denisko, D. & Hoffman, M. M. The Browser Extensible Data (BED) format.
- O'Leary, N. A. *et al.* Reference sequence (RefSeq) database at NCBI: current status, taxonomic
 expansion, and functional annotation. *Nucleic Acids Res.* 44, D733-745 (2016).

- 246 4. R Core Team. R: A Language and Environment for Statistical Computing. (R Foundation for
- 247 Statistical Computing, 2020).
- 248 5. Lawrence, M. et al. Software for Computing and Annotating Genomic Ranges. PLoS Comput. Biol.
- 249 **9**, (2013).
- 250 6. Wickham, H. ggplot2: Elegant Graphics for Data Analysis. (Springer-Verlag New York, 2016).
- 251 7. Sievert, C. Interactive Web-Based Data Visualization with R, plotly, and shiny. (Chapman and
- 252 Hall/CRC, 2020).
- 253 8. Chang, W. et al. shiny: Web Application Framework for R. (2022).
- 254 9. Landrum, M. J. et al. ClinVar: improvements to accessing data. Nucleic Acids Res. 48, D835–D844
- 255 (2020).
- 10. Tate, J. G. et al. COSMIC: the Catalogue Of Somatic Mutations In Cancer. Nucleic Acids Res. 47,
- 257 D941–D947 (2019).
- Hazini, A., Fisher, K. & Seymour, L. Deregulation of HLA-I in cancer and its central importance for
 immunotherapy. J. Immunother. Cancer 9, e002899 (2021).
- 260 12. Fangazio, M. et al. Genetic mechanisms of HLA-I loss and immune escape in diffuse large B cell
- 261 lymphoma. Proc. Natl. Acad. Sci. 118, e2104504118 (2021).
- 262 13. Alcazer, V. & Sujobert, P. Panel Informativity Optimizer: An R Package to Improve Cancer Next-
- 263 Generation Sequencing Panel Informativity. J. Mol. Diagn. 24, 697–709 (2022).

265 Figure Legends

- 266 Figure 1: PanelCat user interface and visualisation options. Users can select tabs with several graphs
- 267 to investigate panel DNA target region coverage. Options include an X/Y scatterplot to compare any
- 268 coverage metric from any previous analysed panel (A), barplots to view or compare absolute or
- 269 relative RefSeq exon base/ClinVar variant/COSMIC mutation coverage per gene (B), a search function
- 270 to compare specific genes of interest across multiple panels (C), a graph to visualise the estimated
- average rate of non-targeted COSMIC CMC tier 1-3 mutations (D), violin plots to compare coverage
- 272 per exon for a transcript of interest between two panels (E), multiple table views to inspect Exons (F),
- 273 ClinVar variants or COSMIC CMC mutations.
- 274 Figure 2: Exon base and mutation coverage in Qiagen PanCancer and TSO500 panels. Coverage of
- exon bases (A,B), ClinVar variants (C,D) and COSMIC CMC mutations (E,F). Note that the TSO uses a
- 276 mask file to filter variant calls at positions with high error rates (shaded purple bars), but the QPC
- 277 does not. Figures B, D, and F show only genes with large relative differences (filtered by fold changes
- 278 of 2, 1.5, and 1.1, respectively)

A PanelCat



Genes shared: AKTI ALK ARIDIA ATRX BRAF CBL CCNDI CCND3 CDK4 CDK6 CDKN2A CDKN2B CREBBP CSFIR CTNNBI EGFR EGFR-ASI ERBB2 ERBB3 ERBB4 ESRI E2H2 FBXW7 FGFRI FGFRI FGFRI FGFRI FLT3 GATAZ GWAII GWAQ H3-3A H3C2 HRAS IDHI IDH2 IGFIR IRAIN JAKI JAKZ JAKI KOR KIT KRAS LOCI06587346 MAPXXI MAPXXI MONZ MOMA HCT NSHE MTGM MYC MYCU MYCUNGO NFI NF2 NOTCH1 NRAS PDGFRA PDGFRB PIK3CA PIK3RI PTCH1 PTEN PTPNII RAFI RBI RET RHOA SETD2 SMARCAA SMARCBI SMO STAT3 TERT TP53 TSCI TSC2 TSPAU31 B PanelCat





C PanelCat

ncov: not covered (excl. masked)



medRxiv preprint doi: https://doi.org/10.1101/2023.06.19.23291594; this version posted June 27, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

width

200

4000

E PanelCat



D PanelCat

Sort by

ncov_targ_bl

-

-

entries



F PanelCat

| anel | | |
|-------|--|--|
| OCAv3 | | |

Scatterplot Barplot Gene NonCovRate Table Exons COSMIC ClinVar Panels NewPanel Info

| Sea | Search: | | | | | | | | | | |
|------|--------------|------------|----------|----------|----------|---------|-------------|---------|-------------|--------|-------------------|
| BRCA | | | | | | | | | | | |
| | group_name 🔅 | seqnames 🗦 | start | end ≑ | strand 👙 | width ‡ | cov_width 👙 | exon_id | transcript | exon 🛊 | covp 🔅 |
| | All | All | All | All | All | All | All | All | All | All | All |
| 970 | BRCA1 | chr17 | 41196312 | 41197819 | - | 1508 | 219 | 748759 | NM_007294.4 | 23 | 0.145225464190981 |
| 971 | BRCA1 | chr17 | 41196312 | 41197819 | | 1508 | 219 | 748760 | NM_007297.4 | 22 | 0.145225464190981 |
| 972 | BRCA1 | chr17 | 41196312 | 41197819 | - | 1508 | 219 | 748761 | NM_007298.3 | 22 | 0.145225464190981 |
| 973 | BRCA1 | chr17 | 41196312 | 41197819 | | 1508 | 219 | 748762 | NM_007299.4 | 22 | 0.145225464190981 |
| 974 | BRCA1 | chr17 | 41196312 | 41197819 | - | 1508 | 219 | 748763 | NM_007300.4 | 24 | 0.145225464190981 |
| 975 | BRCA1 | chr17 | 41196312 | 41197819 | | 1508 | 219 | 748764 | NR_027676.2 | 23 | 0.145225464190981 |
| 976 | BRCA1 | chr17 | 41199660 | 41199720 | - | 61 | 61 | 748765 | NM_007294.4 | 22 | 1 |
| 977 | BRCA1 | chr17 | 41199660 | 41199720 | - | 61 | 61 | 748766 | NM_007297.4 | 21 | 1 |
| 978 | BRCA1 | chr17 | 41199660 | 41199720 | - | 61 | 61 | 748767 | NM_007298.3 | 21 | 1 |
| 979 | BRCA1 | chr17 | 41199660 | 41199720 | - | 61 | 61 | 748768 | NM_007299.4 | 21 | 1 |
| 980 | BRCA1 | chr17 | 41199660 | 41199720 | - | 61 | 61 | 748769 | NM_007300.4 | 23 | 1 |
| 981 | BRCA1 | chr17 | 41199660 | 41199720 | | 61 | 61 | 748770 | NR_027676.2 | 22 | 1 |
| 982 | BRCA1 | chr17 | 41201138 | 41201211 | - | 74 | 74 | 748771 | NM_007294.4 | 21 | 1 |
| 983 | BRCA1 | chr17 | 41201138 | 41201211 | - | 74 | 74 | 748772 | NM_007297.4 | 20 | 1 |
| 984 | BRCA1 | chr17 | 41201138 | 41201211 | - | 74 | 74 | 748773 | NM_007298.3 | 20 | 1 |
| 985 | BRCA1 | chr17 | 41201138 | 41201211 | 5 | 74 | 74 | 748774 | NM_007300.4 | 22 | 1 |
| 986 | BRCA1 | chr17 | 41201138 | 41201211 | - | 74 | 74 | 748775 | NR_027676.2 | 21 | 1 |
| 987 | BRCA1 | chr17 | 41203080 | 41203134 | ÷ | 55 | 55 | 748776 | NM_007294.4 | 20 | 1 |
| 988 | BRCA1 | chr17 | 41203080 | 41203134 | - | 55 | 55 | 748777 | NM_007297.4 | 19 | 1 |
| 989 | BRCA1 | chr17 | 41203080 | 41203134 | - | 55 | 55 | 748778 | NM_007298.3 | 19 | 1 |
| 990 | BRCA1 | chr17 | 41203080 | 41203134 | 41 | 55 | 55 | 748779 | NM_007299.4 | 20 | 1 |

